Journal for ImmunoTherapy of Cancer (Nov 2021)
499 A first-in-human, phase 1/2 clinical trial of TK-8001, a MAGE-A1 directed T cell receptor in patients with advanced-stage solid tumors (The “IMAG1NE”-trial)
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Nov 2021)